Genomic Biomarkers Predict Response to Combined ATR Inhibition and Radiotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39422899.
- Also identified by DOI 10.1158/1078-0432.CCR-24-2306.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
For decades, chemoradiosensitization with checkpoint kinase inhibitors has been proposed but largely unexplored. A recent study reports that the novel ataxia telangiectasia and Rad3-related kinase inhibitor RP-3500 synergizes with radiation to control Atm-/- tumors in vivo. RP-3500 did not radiosensitize wild-type or Brca-1-deficient tumors, highlighting the need for a genotype-tailored approach. See related article by Ng et al., p. 5643.
Medical subject headings
- Ataxia Telangiectasia Mutated Proteins
- Protein Kinase Inhibitors